Sep 15 2015
Fusion IONZ has successfully commissioned and passed a three phase human clinical trial. This clinical trial was conducted by the Dr. Lisa Tully and the Energy Medicine Research Institute. They are an organization specializing in clinical trials for the validation of health product claims. The entire trial was board certified with the use of double blind and placebo techniques. The first phase consisted of a human performance trial, the second phase consisted of a pain relief trial and the third phased concluded with a far infrared output test against other similar infrared products.
"We are so excited to have our products pass a board certified clinical trial," said Matthew Ryncarz, founder of Fusion IONZ. "We have been developing this technology since 2010 and it is very fulfilling to see it perform on this type of stage."
The results showed an average performance increase of 16% across balance, strength, flexibility and muscle endurance. In addition, trial participants noted a 100% increase in their daily energy levels. The pain trial participants noted an average of 28% decrease in body pain after just two weeks of use. The laboratory far infrared strength test showed that Fusion IONZ products were over 25% stronger than the closest non-thermal far infrared competitor.
"With this clinical trial concluded, and the favorable results recorded we are now on a path to use our Fusion IONZ technology in FDA approved medical devices," said Matthew Ryncarz. "We believe our technology is the future of medical and performance technologies."
GPT-4 enhances clinical trial screening accuracy and cuts costs